Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 93

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1
Chunk 93
---
 B warrants and $2,151,464 in net proceeds from a warrant inducement offering in March 2025.
In connection with that transaction, we paid the placement agent fees totaling $153,979, consisting of a 6% commission on gross
proceeds of $138,979 and $15,000 for legal and out-of-pocket expenses to Maxim and $10,877 in direct legal fees.

On
March 16, 2025, Aethlon Medical, Inc. (the “Company”) entered into a
inducement offer to exercise existing Class A and Class B Warrants (the “Agreement”) with a certain accredited and
institutional holder (the “Holder”) of the Company’s outstanding Class A and Class B Warrants issued on May 17,
2024 (the “Existing Warrants”). Pursuant to the Agreement, the Holder, upon exercise, will receive a new unregistered
Common Stock Purchase Warrant (“New Warrant”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
(“Securities Act”), to purchase up to a number of shares equal to 200% of the number of Warrant Shares issued pursuant
to the exercise of Existing Warrants pursuant to this Agreement (the “New Warrant Shares”), which New Warrant shall have
an exercise price per share equal to $0.3736, subject to adjustment as provided in the New Warrant, will be exercisable at any time
on or after six (6) months from the date of issuance and have a term of exercise of five and one-half (5.5) years from the date of
issuance and a reduction of the exercise price of the Existing Warrants to $0.3736 per share, representing the closing price on
March 14, 2025, but only with respect to a cash exercise under the Existing Warrants (as reduced from the current respective
exercise price per share as set forth in the Existing Warrants).

The
closing took place on March 17, 2025. Gross proceeds to the Company from the exercise of the Existing Warrants was  $2,316,320,
prior to deducting closing costs and placement agent fees as further described below. The Company intends to use the net proceeds from
the offering for working capital and general corporate purposes.

As
a result of the Holder exercising the Existing Warrants, the Company issued an aggregate of 775,000